aod9604 and tesamorelin Advanced Metabolic Stack AOD-9604, MOTs-C, Tesamorelin (Fat Burner)

Continual communication with healthcare providers ensures a tailored approach to meet individual health needs

The addition of the N-terminal tyrosine residue was incorporated to facilitate radiolabelling for pharmacokinetic research studies, and has since become a standard part of the compounds structure as used in laboratory research

(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement

In these situations, oral B12 supplements are often useless because the digestive system can't properly absorb the nutrient